The Government-appointed expert panel has recommended granting permission for restricted emergency use authorisation for Bharat Biotech's indigenously developed COVID-19 vaccine Covaxin.

The Special Experts Committee, which reviewed Bharat Biotech's application gave a favourable report to the Drugs Controller General of India.

The DCGI is expected to give its decision on the applications for the COVID-19 vaccine candidates on Sunday.

The vaccine: Covaxin is an indigenous inactivated two-dose SARS-CoV2 vaccine developed by Bharat Biotech along with the Indian Council of Medical Research and the National Institute of Virology. The vaccine has been developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment facility

Efficacy: According to Bharat Biotech, once the vaccine is injected into a human, it "has no potential to infect or replicate, since it is a killed virus". "It just serves to the immune system as a dead virus and mounts an antibody response towards the virus."

Storage: BBV152 or Covaxin is stored between 2 Degree Celsius and 8 Degree Celsius, which is compatible with all national immunization program cold chain requirements.